Hicuity Health Partner Expands Its Relationship with Sarah Bush Lincoln Health Center

New Service Relationship Builds on Existing Tele-ICU Partnership

Hicuity Health, the nation’s leading provider of high-acuity telemedicine services, is expanding its relationship with Sarah Bush Lincoln with the implementation of inpatient telemetry services. Sarah Bush Lincoln has partnered with Hicuity Health for tele-ICU services since 2015. The success of this ongoing critical care collaboration influenced the decision to extend the partnership to include the new telemetry services.

Hicuity Health’s Remote Cardiac Telemetry monitoring provides hospitals with 24/7 monitoring by trained and certified telemetry technicians located in dedicated technology-enabled care centers. Hicuity’s nurse-managed technicians monitor cardiac at-risk patients throughout the hospital, identifying cardiac abnormalities, and then urgently reporting them to the bedside team. Partnering with Hicuity Health’s remote monitoring service engages trained monitoring of patient waveforms and allows bedside nurses to maintain their focus on patient care rather than focusing on computer monitors and responding to false alarms.

“As a tele-ICU partner, we have been impressed by Hicuity Health’s support and collaborative approach. The expansion of our relationship to include telemetry services is a direct result of our years of experience with Hicuity. Simply put, we wanted to ensure that we were working with a team that would be an expert partner to our clinical team,” Sandra Miller, SBL VP Patient Care Continuum, CNO, said. “The decision to expand the relationship to include remote telemetry services is a strategic decision from both an operational and clinical perspective.”

“We are pleased to extend our long-term relationship with Sarah Bush Lincoln to include telemetry services,” said Lou Silverman, Chief Executive Officer of Hicuity Health. “Its addition of Hicuity Health’s Remote Cardiac Telemetry services emphasizes the hospital’s commitment to providing its staff with the support needed to ensure high quality patient care.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version